BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang Y, Gao R, Cao C, Forbes L, Li J, Freeberg S, Fredenburg KM, Justice JM, Silver NL, Wu L, Varma S, West R, Licht JD, Zajac-Kaye M, Kentsis A, Kaye FJ. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma. Oral Oncol 2019;98:147-55. [PMID: 31606723 DOI: 10.1016/j.oraloncology.2019.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Yusenko MV, Klempnauer K. Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824. BBA Advances 2022;2:100034. [DOI: 10.1016/j.bbadva.2021.100034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Riedel SS, Lu C, Xie HM, Nestler K, Vermunt MW, Lenard A, Bennett L, Speck NA, Hanamura I, Lessard JA, Blobel GA, Garcia BA, Bernt KM. Intrinsically disordered Meningioma-1 stabilizes the BAF complex to cause AML. Mol Cell 2021;81:2332-2348.e9. [PMID: 33974912 DOI: 10.1016/j.molcel.2021.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Biyanee A, Yusenko MV, Klempnauer K. Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner. Cells 2022;11:1162. [DOI: 10.3390/cells11071162] [Reference Citation Analysis]
4 Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad RI. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol 2021;119:105366. [PMID: 34091189 DOI: 10.1016/j.oraloncology.2021.105366] [Reference Citation Analysis]
5 Nightingale J, Lum B, Ladwa R, Simpson F, Panizza B. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochim Biophys Acta Rev Cancer 2021;1875:188523. [PMID: 33600823 DOI: 10.1016/j.bbcan.2021.188523] [Reference Citation Analysis]
6 Yusenko MV, Biyanee A, Andersson MK, Radetzki S, von Kries JP, Stenman G, Klempnauer KH. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. Cancer Lett 2021;520:132-42. [PMID: 34256093 DOI: 10.1016/j.canlet.2021.07.010] [Reference Citation Analysis]